Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer.

Schreiber LM, Urbiola C, Das K, Spiesschaert B, Kimpel J, Heinemann F, Stierstorfer B, Müller P, Petersson M, Erlmann P, von Laer D, Wollmann G.

Br J Cancer. 2019 Sep 18. doi: 10.1038/s41416-019-0574-7. [Epub ahead of print]

PMID:
31530903
2.

Measles Elimination: Identifying Susceptible Sub-Populations to Tailor Immunization Strategies.

Kreidl P, Ammerer D, Würzner R, Luckner Hornischer A, von Laer D, Borena W.

Viruses. 2019 Aug 20;11(8). pii: E765. doi: 10.3390/v11080765.

3.

RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization.

Wilmschen S, Schneider S, Peters F, Bayer L, Issmail L, Bánki Z, Grunwald T, von Laer D, Kimpel J.

Vaccines (Basel). 2019 Jul 3;7(3). pii: E59. doi: 10.3390/vaccines7030059.

4.

Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.

Pipperger L, Koske I, Wild N, Müllauer B, Krenn D, Stoiber H, Wollmann G, Kimpel J, von Laer D, Bánki Z.

J Virol. 2019 Aug 28;93(18). pii: e00567-19. doi: 10.1128/JVI.00567-19. Print 2019 Sep 15.

5.

Anal Ureaplasma spp. positivity among HIV positive men who have sex with men may be associated with high-risk-type HPV infections.

Borena W, Kruis S, Kitchen M, Taylor N, Gisinger M, Oberkofler H, Stoiber H, Zangerle R, von Laer D, Sarcletti M.

Int J Infect Dis. 2019 Jul;84:75-79. doi: 10.1016/j.ijid.2019.04.025. Epub 2019 May 2.

6.

Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.

Koske I, Rössler A, Pipperger L, Petersson M, Barnstorf I, Kimpel J, Tripp CH, Stoitzner P, Bánki Z, von Laer D.

Int J Cancer. 2019 Oct 1;145(7):1958-1969. doi: 10.1002/ijc.32325. Epub 2019 Apr 29.

PMID:
30972741
7.

Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.

Bresk CA, Hofer T, Wilmschen S, Krismer M, Beierfuß A, Effantin G, Weissenhorn W, Hogan MJ, Jordan APO, Gelman RS, Montefiori DC, Liao HX, Schmitz JE, Haynes BF, von Laer D, Kimpel J.

Viruses. 2019 Feb 15;11(2). pii: E159. doi: 10.3390/v11020159.

8.
9.

Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.

Urbiola C, Santer FR, Petersson M, van der Pluijm G, Horninger W, Erlmann P, Wollmann G, Kimpel J, Culig Z, von Laer D.

Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31556. [Epub ahead of print]

10.

Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model.

Weiser C, Petkova MV, Rengstl B, Döring C, von Laer D, Hartmann S, Küppers R, Hansmann ML, Newrzela S.

Oncotarget. 2018 Mar 23;9(22):15942-15951. doi: 10.18632/oncotarget.24639. eCollection 2018 Mar 23.

11.

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.

Kimpel J, Urbiola C, Koske I, Tober R, Banki Z, Wollmann G, von Laer D.

Viruses. 2018 Mar 2;10(3). pii: E108. doi: 10.3390/v10030108.

12.

Epidemiology and clinical profile of pathogens responsible for the hospitalization of children in Sousse area, Tunisia.

Brini I, Guerrero A, Hannachi N, Bouguila J, Orth-Höller D, Bouhlel A, Boughamoura L, Hetzer B, Borena W, Schiela B, Von Laer D, Boukadida J, Stoiber H.

PLoS One. 2017 Nov 17;12(11):e0188325. doi: 10.1371/journal.pone.0188325. eCollection 2017.

13.

No molecular or serological evidence of Zikavirus infection among healthy blood donors living in or travelling to regions where Aedes albopictus circulates.

Borena W, Hofer T, Stiasny K, Aberle SW, Gaber M, von Laer D, Schennach H.

PLoS One. 2017 May 24;12(5):e0178175. doi: 10.1371/journal.pone.0178175. eCollection 2017.

14.

Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression.

Kalkavan H, Sharma P, Kasper S, Helfrich I, Pandyra AA, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle PA, Wollmann G, von Laer D, Drexler I, Rathbun J, Cannon PM, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang PA, Lang KS.

Nat Commun. 2017 Mar 1;8:14447. doi: 10.1038/ncomms14447.

15.

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.

Dold C, Rodriguez Urbiola C, Wollmann G, Egerer L, Muik A, Bellmann L, Fiegl H, Marth C, Kimpel J, von Laer D.

Mol Ther Oncolytics. 2016 Sep 28;3:16021. eCollection 2016.

16.

Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies.

Roellecke K, Virts EL, Einholz R, Edson KZ, Altvater B, Rossig C, von Laer D, Scheckenbach K, Wagenmann M, Reinhardt D, Kramm CM, Rettie AE, Wiek C, Hanenberg H.

Gene Ther. 2016 Jul;23(7):615-26. doi: 10.1038/gt.2016.38. Epub 2016 May 19.

PMID:
27092941
17.

Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors.

Zhou Q, Uhlig KM, Muth A, Kimpel J, Lévy C, Münch RC, Seifried J, Pfeiffer A, Trkola A, Coulibaly C, von Laer D, Wels WS, Hartwig UF, Verhoeyen E, Buchholz CJ.

J Immunol. 2015 Sep 1;195(5):2493-501. doi: 10.4049/jimmunol.1500956. Epub 2015 Jul 31.

18.

Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blot.

Pichler R, Borena W, Schäfer G, Manzl C, Culig Z, List S, Neururer S, Von Laer D, Heidegger I, Klocker H, Horninger W, Steiner H, Brunner A.

World J Urol. 2015 Dec;33(12):2145-51. doi: 10.1007/s00345-015-1539-y. Epub 2015 Mar 19.

PMID:
25786709
19.

C peptides as entry inhibitors for gene therapy.

Egerer L, Kiem HP, von Laer D.

Adv Exp Med Biol. 2015;848:191-209. doi: 10.1007/978-1-4939-2432-5_10. Review.

PMID:
25757622
20.

A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells.

MacLean AG, Walker E, Sahu GK, Skowron G, Marx P, von Laer D, Junghans RP, Braun SE.

J Med Primatol. 2014 Oct;43(5):341-8. doi: 10.1111/jmp.12137. Epub 2014 Aug 20.

21.

Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1.

Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, Kalinke U, Vivier E, Jonjic S, Oxenius A.

Immunity. 2014 Jun 19;40(6):961-73. doi: 10.1016/j.immuni.2014.05.003. Epub 2014 Jun 5.

22.

Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.

Muik A, Stubbert LJ, Jahedi RZ, Geiβ Y, Kimpel J, Dold C, Tober R, Volk A, Klein S, Dietrich U, Yadollahi B, Falls T, Miletic H, Stojdl D, Bell JC, von Laer D.

Cancer Res. 2014 Jul 1;74(13):3567-78. doi: 10.1158/0008-5472.CAN-13-3306. Epub 2014 May 8.

23.

VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.

Tober R, Banki Z, Egerer L, Muik A, Behmüller S, Kreppel F, Greczmiel U, Oxenius A, von Laer D, Kimpel J.

J Virol. 2014 May;88(9):4897-907. doi: 10.1128/JVI.03276-13. Epub 2014 Feb 19.

24.

Mathematical modeling of oncogenesis control in mature T-cell populations.

Gerdes S, Newrzela S, Glauche I, von Laer D, Hansmann ML, Roeder I.

Front Immunol. 2013 Nov 21;4:380. doi: 10.3389/fimmu.2013.00380. eCollection 2013.

25.

Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model.

Younan PM, Polacino P, Kowalski JP, Peterson CW, Maurice NJ, Williams NP, Ho O, Trobridge GD, Von Laer D, Prlic M, Beard BC, DeRosa S, Hu SL, Kiem HP.

Blood. 2013 Jul 11;122(2):179-87. doi: 10.1182/blood-2013-01-482224. Epub 2013 May 29.

26.

Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.

Heinrich T, Rengstl B, Muik A, Petkova M, Schmid F, Wistinghausen R, Warner K, Crispatzu G, Hansmann ML, Herling M, von Laer D, Newrzela S.

Mol Ther. 2013 Jun;21(6):1160-8. doi: 10.1038/mt.2013.67. Epub 2013 Apr 23.

27.

A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity.

Brauer F, Schmidt K, Zahn RC, Richter C, Radeke HH, Schmitz JE, von Laer D, Egerer L.

Antimicrob Agents Chemother. 2013 Feb;57(2):679-88. doi: 10.1128/AAC.01152-12. Epub 2012 Nov 12.

28.

Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responses.

Ejaz A, Ammann CG, Werner R, Huber G, Oberhauser V, Hörl S, Schimmer S, Dittmer U, von Laer D, Stoiber H, Bánki Z.

PLoS One. 2012;7(9):e45102. doi: 10.1371/journal.pone.0045102. Epub 2012 Sep 17.

29.

Comparison of three humanized mouse models for adoptive T cell transfer.

Volk A, Hartmann S, Muik A, Geiss Y, Königs C, Dietrich U, von Laer D, Kimpel J.

J Gene Med. 2012 Aug;14(8):540-8. doi: 10.1002/jgm.2652.

PMID:
22847974
30.

T-cell receptor diversity prevents T-cell lymphoma development.

Newrzela S, Al-Ghaili N, Heinrich T, Petkova M, Hartmann S, Rengstl B, Kumar A, Jäck HM, Gerdes S, Roeder I, Hansmann ML, von Laer D.

Leukemia. 2012 Dec;26(12):2499-507. doi: 10.1038/leu.2012.142. Epub 2012 May 30.

PMID:
22643706
31.

Lens epithelium-derived growth factor/p75 qualifies as a target for HIV gene therapy in the NSG mouse model.

Vets S, Kimpel J, Volk A, De Rijck J, Schrijvers R, Verbinnen B, Maes W, Von Laer D, Debyser Z, Gijsbers R.

Mol Ther. 2012 May;20(5):908-17. doi: 10.1038/mt.2012.6. Epub 2012 Feb 14.

32.

Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy.

Muik A, Dold C, Geiß Y, Volk A, Werbizki M, Dietrich U, von Laer D.

J Mol Med (Berl). 2012 Aug;90(8):959-70. doi: 10.1007/s00109-012-0863-6.

33.

Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.

Newrzela S, Cornils K, Heinrich T, Schläger J, Yi JH, Lysenko O, Kimpel J, Fehse B, von Laer D.

Mol Med. 2011;17(11-12):1223-32. doi: 10.2119/molmed.2010.00193. Epub 2011 Jul 27.

34.

Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect.

Preuss E, Muik A, Weber K, Otte J, von Laer D, Fehse B.

J Mol Med (Berl). 2011 Nov;89(11):1113-24. doi: 10.1007/s00109-011-0777-8. Epub 2011 Jun 23.

PMID:
21698427
35.

Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism.

Muik A, Kneiske I, Werbizki M, Wilflingseder D, Giroglou T, Ebert O, Kraft A, Dietrich U, Zimmer G, Momma S, von Laer D.

J Virol. 2011 Jun;85(11):5679-84. doi: 10.1128/JVI.02511-10. Epub 2011 Mar 30.

36.

Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection.

Egerer L, Volk A, Kahle J, Kimpel J, Brauer F, Hermann FG, von Laer D.

Mol Ther. 2011 Jul;19(7):1236-44. doi: 10.1038/mt.2011.30. Epub 2011 Mar 1.

37.

Cell and virus genetics at the roots of gene therapy, retrovirology, and hematopoietic stem cell biology: Wolfram Ostertag (1937-2010).

Stocking C, Grez M, Fehse B, von Laer D, Itoh K, Prassolov V, Nowock J, Kühlcke K, Just U, Schröder T, Klump H, Schiedlmeier B, Grassman E, Meyer J, Li Z, Schambach A, Modlich U, Kustikova O, Galla M, Bode J, Zander A, Baum C.

Hum Gene Ther. 2010 Nov;21(11):1501-3. doi: 10.1089/hum.2010.1901. No abstract available.

PMID:
21091034
38.

Complement opsonization enhances friend virus infection of B cells and thereby amplifies the virus-specific CD8+ T cell response.

Bila C, Oberhauser V, Ammann CG, Ejaz A, Huber G, Schimmer S, Messer R, Pekna M, von Laer D, Dittmer U, Hasenkrug KJ, Stoiber H, Bánki Z.

J Virol. 2011 Jan;85(2):1151-5. doi: 10.1128/JVI.01821-10. Epub 2010 Nov 3.

39.

Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection.

Kimpel J, Braun SE, Qiu G, Wong FE, Conolle M, Schmitz JE, Brendel C, Humeau LM, Dropulic B, Rossi JJ, Berger A, von Laer D, Johnson RP.

PLoS One. 2010 Aug 23;5(8):e12357. doi: 10.1371/journal.pone.0012357.

40.

An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy.

Vogler I, Newrzela S, Hartmann S, Schneider N, von Laer D, Koehl U, Grez M.

Mol Ther. 2010 Jul;18(7):1330-8. doi: 10.1038/mt.2010.83. Epub 2010 May 11.

41.

Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation.

Kuçi S, Rettinger E, Voss B, Weber G, Stais M, Kreyenberg H, Willasch A, Kuçi Z, Koscielniak E, Klöss S, von Laer D, Klingebiel T, Bader P.

Haematologica. 2010 Sep;95(9):1579-86. doi: 10.3324/haematol.2009.019885. Epub 2010 Apr 7.

42.

TK.007: A novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy.

Preuss E, Treschow A, Newrzela S, Brücher D, Weber K, Felldin U, Alici E, Gahrton G, von Laer D, Dilber MS, Fehse B.

Hum Gene Ther. 2010 Aug;21(8):929-41. doi: 10.1089/hum.2009.042.

PMID:
20201626
43.

CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties.

Kuçi S, Kuçi Z, Kreyenberg H, Deak E, Pütsch K, Huenecke S, Amara C, Koller S, Rettinger E, Grez M, Koehl U, Latifi-Pupovci H, Henschler R, Tonn T, von Laer D, Klingebiel T, Bader P.

Haematologica. 2010 Apr;95(4):651-9. doi: 10.3324/haematol.2009.015065. Epub 2010 Feb 23.

44.

Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection.

Trobridge GD, Wu RA, Beard BC, Chiu SY, Muñoz NM, von Laer D, Rossi JJ, Kiem HP.

PLoS One. 2009 Nov 2;4(11):e7693. doi: 10.1371/journal.pone.0007693.

45.

Peaceful coexistence or clonal dominance?

von Laer D.

Blood. 2009 Oct 22;114(17):3507-8. doi: 10.1182/blood-2009-08-238097. No abstract available.

46.

Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo.

Kiem HP, Wu RA, Sun G, von Laer D, Rossi JJ, Trobridge GD.

Gene Ther. 2010 Jan;17(1):37-49. doi: 10.1038/gt.2009.118. Epub 2009 Sep 10.

47.

Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy.

Huszthy PC, Giroglou T, Tsinkalovsky O, Euskirchen P, Skaftnesmo KO, Bjerkvig R, von Laer D, Miletic H.

PLoS One. 2009 Jul 20;4(7):e6314. doi: 10.1371/journal.pone.0006314.

48.

Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46.

Hermann FG, Egerer L, Brauer F, Gerum C, Schwalbe H, Dietrich U, von Laer D.

J Virol. 2009 May;83(10):4844-53. doi: 10.1128/JVI.00666-08. Epub 2009 Mar 11.

49.

Protein scaffold and expression level determine antiviral activity of membrane-anchored antiviral peptides.

Hermann FG, Martinius H, Egelhofer M, Giroglou T, Tonn T, Roth SD, Zahn R, Schult-Dietrich P, Alexandrov A, Dietrich U, Baum C, von Laer D.

Hum Gene Ther. 2009 Apr;20(4):325-36. doi: 10.1089/hum.2006.158.

PMID:
19267665
50.

T cell culture for gammaretroviral transfer.

Newrzela S, Gunda B, von Laer D.

Methods Mol Biol. 2009;506:71-82. doi: 10.1007/978-1-59745-409-4_6.

PMID:
19110620

Supplemental Content

Loading ...
Support Center